Skip Navigation



Human Molecular Genetics Advance Access published online on November 13, 2008
Human Molecular Genetics, doi:10.1093/hmg/ddn382
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
18/3/546    most recent
ddn382v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Meyer, K.
Right arrow Articles by Schümperli, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, K.
Right arrow Articles by Schümperli, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Rescue of a severe mouse model for Spinal Muscular Atrophy by U7 snRNA-mediated splicing modulation

Kathrin Meyer1,3, Julien Marquis1,3,4, Judith Trüb1, Rachel Nlend Nlend1, Sonia Verp2, Marc-David Ruepp1, Hans Imboden1, Isabelle Barde2, Didier Trono2 and Daniel Schümperli1,*

1 Institute of Cell Biology, University of Bern, Bern, Switzerland, EPFL Lausanne, Switzerland 2 Laboratory of Virology and Genetics, School of Life Sciences, EPFL Lausanne, Switzerland

* Correspondence to: Daniel Schümperli, Institute of Cell Biology, University of Bern, Baltzerstrasse 4, CH-3012 Bern, Switzerland. E-mail: daniel.schuemperli{at}izb.unibe.ch, phone: +41 31 631 4675, fax: +41 31 631 4616.

Received October 9, 2008; Revised November 10, 2008; Accepted November 10, 2008

In Spinal Muscular Atrophy (SMA), the leading genetic cause of early childhood death, the survival motor neuron 1 gene (SMN1) is deleted or inactivated. The nearly identical SMN2 gene has a silent mutation that impairs the utilisation of exon 7 and the production of functional protein. It has been hypothesised that therapies boosting SMN2 exon 7 inclusion might prevent or cure SMA. Exon 7 inclusion can be stimulated in cell culture by oligonucleotides or intracellularly expressed RNAs, but evidence for an in vivo improvement of SMA symptoms is lacking. Here we unambiguously confirm the above hypothesis by showing that a bifunctional U7 snRNA that stimulates exon 7 inclusion, when introduced by germ-line transgenesis, can efficiently complement the most severe mouse SMA model. These results are significant for the development of a somatic SMA therapy, but may also provide new means to study pathophysiological aspects of this devastating disease.

3 Authors who contributed equally to this work and should be considered joint first authors

4 Present adress: Laboratory of Virology and Genetics, School of Life Sciences, EPFL Lausanne, Switzerland


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. E.R. Butchbach, J. Singh, M. Thorsteinsdottir, L. Saieva, E. Slominski, J. Thurmond, T. Andresson, J. Zhang, J. D. Edwards, L. R. Simard, et al.
Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy
Hum. Mol. Genet., November 25, 2009; (2009) ddp510v2.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.